NVDA gained a massive 197% since our AI first added it in November - is it time to sell? 🤔Read more

UPDATE 2-Boston Scientific to expand in Europe with Symetis buy

Published 2017-03-30, 09:24 a/m
© Reuters.  UPDATE 2-Boston Scientific to expand in Europe with Symetis buy
BSX
-
NVCN
-

* Symetis' Acurate devices seen complementary to Boston Scientific's Lotus valve devices

* Deal expected to close in Q2

* Boston Scientific shares were down 1.3 pct premarket (Adds details, analyst comment, shares)

March 30 (Reuters) - Boston Scientific Corp (NYSE:BSX) BSX.N said on Thursday it would buy Swiss medical device maker Symetis SA for $435 million, a deal that will help the U.S. company expand in the European market.

Boston Scientific in February recalled its Lotus valve devices from Europe and other regions following reports of a faulty locking mechanism.

These devices are used in TAVR, a minimally invasive procedure, to replace a narrowed aortic valve that fails to open properly. Acurate systems would complement Boston Scientific's Lotus valve devices, the company said.

The acquisition would allow Boston Scientific to enter into the European market immediately, Evercore ISI analyst Vijay Kumar said in a client note.

Boston Scientific said it expects the Lotus valve devices to return to those markets in the fourth quarter. transaction is a bit of a head scratcher and will likely cause some concern on the Street about Boston's Lotus program, J.P. Morgan analyst Michael Weinstein said.

Weinstein also noted Symetis had $40 million in TAVR sales in Europe last year and over the last few years has seen only limited growth.

Following the deal, Symetis said it had halted its IPO launch, its second attempt to go public.

The company was expecting to raise up to 61.5 million euros ($66 million) and list on the Euronext Paris by March 31. Scientific said it expects the deal to slightly boost results in 2018 on an adjusted basis, and rise thereafter. The deal is expected to close in the second quarter, the company said. in February acquired another privately held German medical device maker Middle Peak Medical to expand its portfolio in structural heart devices.

Shares of Boston Scientific, which bought Neovasc Inc 's NVCN.TO tissue processing technology and facility in December, were down 1.3 percent at $24.40 in light premarket trading on Thursday.

($1 = 0.93 euros)

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.